Medtronic is the world’s largest medical technology company, offering an unprecedented breadth and depth of innovative therapies to fulfill our Mission of alleviating pain, restoring health, and extending life. Last year, more than 10 million people benefited from our medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.
With a global reach that extends to more than 140 countries, we have a deep understanding of many universal healthcare challenges. We’re using our experience, extensive partnerships, and the passion of 46,000 employees to help transform healthcare worldwide by improving outcomes, expanding access, and enhancing value.
For more than 30 years Medtronic Africa has been committed to the challenge of providing products and therapies to both the public and private healthcare sector of South Africa, alleviating pain, restoring health and extending life in patients with conditions such as cardiovascular and vascular diseases, spinal conditions as well as neurological disorders and diabetes. The growth of the company is testament to the staff’s commitment to deliver the Medtronic mission.
Contact
Woodmead North Office Park
54 Maxwell Drive
Woodmead
Jukskeiview
2195
Gauteng
Tel: 011 260 9300
Peter Fuller provides us with an update on the integration of Covidien businesses, and explains how Medtronic is bringing innovation to South African patients and contributing to the improvement of the…
Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up…
Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the…
African healthcare and pharma are moving from ambition to action. Regular PharmaBoardroom contributor Lenias Hwenda explains how, after years of over-dependence on global supply chains, fragmented regulation, and limited local…
Africa accounts for 19 percent of the world’s population and one-quarter of the global disease burden. However, for a host of reasons – both real and perceptual – the continent…
Writing in the July 2025 edition of DIA’s Global Forum magazine, Alex Juma Ismail of the African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) and Vicki Gold,…
Building on the recent controversy over Tanzania’s handling of a suspected Marburg virus outbreak, Medicines for Africa’s Lenias Hwenda explores how African nations often face disproportionate consequences for outbreak transparency—penalties…
John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into…
The IFPMA’s Sarah Adam, writing in the July 2024 edition of DIA’s Global Forum magazine, looks back on an insightful discussion on the progress towards an African Medicines Agency at…
Several major scientific breakthroughs in HIV prevention and treatment in the past 40 years have successfully transformed HIV from a near-certain ‘death sentence’ to a manageable chronic disease where many…
In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step…
A leading voice in the global fight against HIV, Professor Linda-Gail Bekker works across both scientific research and activism. As CEO and founder of the Desmond Tutu Health Foundation, Prof…
Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to…
See our Cookie Privacy Policy Here
